Valeant Pharmaceuticals International, Inc. (VRX) Files Form 4 Insider Buying : Thomas W. Sr. Ross Buys 4,000 Shares

Valeant Pharmaceuticals International, Inc. (VRX): Thomas W. Sr. Ross , director of Valeant Pharmaceuticals International, Inc. purchased 4,000 shares on Jun 13, 2016. The Insider buying transaction was reported by the company on Jun 27, 2016 to the Securities and Exchange Commission. The shares were purchased at $24.40 per share for a total value of $97,600.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 13, 2016, Joseph C Papa (CEO) purchased 202,000 shares at $24.48 per share price.On Nov 9, 2015, J. Michael Pearson (Chief Executive Officer) sold 1,297,399 shares at $78.53 per share price.Also, On Oct 22, 2015, Ronald Harold Farmer (director) purchased 1,500 shares at $175.90 per share price.On Aug 3, 2015, Robert L. Rosiello (CFO) purchased 7,875 shares at $255.62 per share price.

Shares of Valeant Pharmaceuticals Intl Inc (VRX) ended Friday, Jun 24, 2016 session in red amid volatile trading. The shares closed down -1.98 points or -8.90% at $20.27 with 2,79,77,033 shares getting traded. Post opening the session at $21.16, the shares hit an intraday low of $20.211 and an intraday high of $21.48 and the price vacillated in this range throughout the day. The company has a market cap of $6,953 M and the number of outstanding shares has been calculated to be 34,30,30,280 shares. The 52-week high of Valeant Pharmaceuticals Intl Inc is $263.81 and the 52-week low is $20.211.

Valeant Pharmaceuticals Intl Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.Valeant Pharmaceuticals Intl Inc is Downgraded by JP Morgan to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Jun 23, 2016.Valeant Pharmaceuticals Intl Inc is Reiterated by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 33 from a previous price target of $58 . The Rating was issued on Jun 8, 2016.Valeant Pharmaceuticals Intl Inc is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 55 from a previous price target of $65 . The Rating was issued on Jun 8, 2016.Valeant Pharmaceuticals Intl Inc is Reiterated by Mizuho to Underperform while Lowering the Price Target of the company shares to $ 11 from a previous price target of $18 . The Rating was issued on Jun 8, 2016.Valeant Pharmaceuticals Intl Inc is Reiterated by Rodman & Renshaw to Buy while Lowering the Price Target of the company shares to $ 102 from a previous price target of $105 . The Rating was issued on May 3, 2016.

Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.

Leave a Reply

Valeant Pharmaceuticals Intl Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Valeant Pharmaceuticals Intl Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.